BUZZ-Chime Financial shares rise as the company is set to join the S&P MidCap Index
路透社2026/11/16 12:57November 16 - ** The fintech company Chime Financial (CHYM.O) saw its share price rise 2.8% in pre-market trading to $34.50, as it is set to join the S&P MidCap 400 Index (.IDX) this week.
** S&P Dow Jones Indices announced on Friday evening (link) that CHYM will replace NorthWestern Energy NWE.O in the IDX starting Wednesday, November 18.
** The utility company NWE has been acquired by Black Hills Corp (link); the merged company will remain in the IDX and be renamed (link) Bright Horizon Energy Corp HZN.N.
** Stephens analyst Melissa Roberts noted in a research report that passive funds will need to purchase nearly 31 million CHYM shares, which translates to nearly eight days of buying demand.
** CHYM, headquartered in San Francisco, has approximately 383.8 million shares outstanding, with a market capitalization of about $13 billion.
** As of Friday's close, the stock is up 33% year-to-date, with a 20% gain this month; the company went public in June 2025 via IPO (link) at a price of $27 per share.
** According to London Stock Exchange Group (LSEG) data, 24 out of 26 analysts rate the stock as “strong buy” or “buy,” while two rate it as “hold”; the median target price is $41, up from $33 three months ago.
(To assist non-English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss arising from its use.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Eli Lilly (LLY.US) makes another move! Acquires Calytrix for up to $1.5 billion, betting on rare blood cancer therapies
Eli Lilly has agreed to acquire the privately held Calytrix Bio Inc. in a deal valued at up to $1.5 billion.

Nvidia Shares Fall Premarket as Analysts Warn of Leadership Uncertainty -- Market Talk
BUZZ-Aramark shares fall as fourth-quarter profits miss expectations